For Immediate Release

2016.11.30

ompany name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Japanese Research Partners Selected for 2016 TaNeDS Collaborative Drug Discovery Project

Tokyo, Japan (November 30, 2016)－ Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners in Japan for its 2016 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project.

TaNeDS, which began in 2011 as part of Daiichi Sankyo's open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon initiate collaborative research with this year's selected parties.

1. Total entries: 209

2. Selected parties: 21

3. Selections by entry type

Project type

Entries

Passed second selections

Final selections

Total

209

26

21

a. Drug discovery target verification

123

14

10

b. Drug discovery target investigation

49

2

2

c. Drug discovery technology development/verification

73

8

8

d. Pharmaceutical technology

8

2

1

* Project type contains 4 categories, thus entries with multiple categories are counted once for each category.

4. Selections by research theme

Desired research themes

Entries

Passed second selections

Final

selections

Total

209*

26

21

・Oncology

131

8

5

・Other disorders

77

9

8

・Regenerative medicine/cell therapy

22

1

1

・Chemical biology

3

0

0

・Biologics

23

1

1

・DDS

15

1

1

・Pathological model/unique cell-based assays/vital imaging

4

0

0

・In silico models related to drug effect estimates/pathological clarification

8

2

2

・ADME (Drug Absorption, Distribution, Metabolism, Excretion)

17

1

1

・Drug safety

2

0

0

・Measuring technology related to biomarkers

8

1

1

・Structure-based-drug-discovery

1

0

0

・Pharmaceutical Formulation technology research

3

2

1

・Drug analysis technology

0

0

0

・Industrial chemical synthetic technology

5

0

0

* Entries with multiple themes are counted once for each theme.

For more information about the TaNeDS program, please visit the Daiichi Sankyo corporate website (in Japanese):

http://www.daiichisankyo.co.jp/corporate/rd/taneds/

Daiichi Sankyo Co. Ltd. published this content on 30 November 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 November 2016 01:04:12 UTC.

Original documenthttp://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006547.html

Public permalinkhttp://www.publicnow.com/view/E42266CA0050A3E76840F1CA83E5E5A56234339C